Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.33 |
| ▸ | ELANE | P08246 | 3/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | TK1 | P04183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348878 | 0.81 | PRKCA (0.39) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL3517297 | 0.80 | PRKCA (0.42) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL8816807 | 0.80 | PRKCA (0.42) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL561844 | 0.79 | PRKCA (0.38) | PRKCAPOLBGAANPSR1ELANE | |
| SCHEMBL28019636 | 0.77 | PRKCA (0.43) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL9714746 | 0.76 | PRKCA (0.39) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL13647509 | 0.75 | MAPK1 (0.47) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL9866275 | 0.75 | PRKCA (0.42) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL7089654 | 0.75 | PRKCA (0.42) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL15976179 | 0.74 | BTN3A1 (0.39) | PRKCAPOLBGAANPSR1BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023555-B2 | NSAIDs derivatives and uses thereof | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2017-09-14 | — | — | US | disclosed |
| US-9688607-B2 | No- and H2S-releasing compounds | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170174651-A1 | Method of Priming Plants Against Abiotic Stress Factors | CYPRUS UNIVERSITY OF TECHNOLOGY (CY) | 2017-06-22 | — | — | US | disclosed |
| US-20150376162-A1 | NSAIDs DERIVATIVES AND USES THEREOF | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2015-12-31 | — | — | US | disclosed |
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | PTGS1, NOS2, NOS1 | PRKCA 1435/4885POLB 4346/4885GAA 2445/4885 |
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | NOS2, NOS3, NOS1 | PRKCA 1661/4885POLB 3358/4885GAA 3291/4885 |
| US-10023555-B2 | NSAIDs derivatives and uses thereof | PTGES, PTGES3, PTGS1 | PRKCA 3453/4885POLB 4736/4885GAA 3531/4885 |
| US-20150376162-A1 | NSAIDs DERIVATIVES AND USES THEREOF | PTGES, PTGES3, PTGS1 | PRKCA 3453/4885POLB 4736/4885GAA 3531/4885 |
| US-20170174651-A1 | Method of Priming Plants Against Abiotic Stress Factors | NOS2, NOS1, HSF1 | PRKCA 1417/4885POLB 2444/4885GAA 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.